Abstract
Although hepatitis B serology screening has been recommended for HIV care, it has not been routinely performed. We aimed to assess compliance and timing of hepatitis B serology screening among HIV-infected patients in a resource-limited setting. A cross-sectional study was conducted in Thailand. Compliance, timing of hepatitis B serology screening, and factors associated with no HBsAg screening were determined. A total of 416 HIV-infected patients with 61% males were enrolled. Median (range) age at HIV diagnosis was 34 (16-75) years and 92% had heterosexual risk. Proportion of HBsAg screening and prevalence of positive HBsAg were 69.2% and 9.0%, respectively. There was no difference in the proportion of no HBsAg screening during the period 1990-2008 (p = 0.865). Proportion of anti-HBs and anti-HBc screening were 40.9% and 21.2%, respectively. HBsAg was screened before or on the day of anti-HIV testing in 9.1% and before antiretroviral therapy (ART) initiation in 27.2%. By Kaplan-Meier analysis, median time from anti-HIV testing to HBsAg screening was 55.9 (95% confidence interval [CI] 43.9, 68.3) months. By multivariate logistic regression, duration of HIV infection (odds ratio [OR] 1.14; 95% CI 1.07, 1.21), no anti-HBs screening (OR 1.65; 95% CI 1.4-2.63), and no anti-HCV screening (OR 2.60; 95% CI 1.62, 4.17) were associated with no HBsAg screening before ART initiation. In conclusion, compliance with hepatitis B serology screening was relatively low and late. Educational program regarding hepatitis B serology screening, identification of barriers, and interventions to eliminate these barriers in resource-limited settings are crucial to improve HIV care.
Keywords: Compliance, hepatitis B virus, HIV, screening, Thailand
Current HIV Research
Title: Late and Low Compliance with Hepatitis B Serology Screening Among HIV-Infected Patients in a Resource-Limited Setting: An Issue to Improve HIV Care
Volume: 9 Issue: 1
Author(s): Sasisopin Kiertiburanakul, Darunee Chotiprasitsakul, Kalayanee Atamasirikul and Somnuek Sungkanuparph
Affiliation:
Keywords: Compliance, hepatitis B virus, HIV, screening, Thailand
Abstract: Although hepatitis B serology screening has been recommended for HIV care, it has not been routinely performed. We aimed to assess compliance and timing of hepatitis B serology screening among HIV-infected patients in a resource-limited setting. A cross-sectional study was conducted in Thailand. Compliance, timing of hepatitis B serology screening, and factors associated with no HBsAg screening were determined. A total of 416 HIV-infected patients with 61% males were enrolled. Median (range) age at HIV diagnosis was 34 (16-75) years and 92% had heterosexual risk. Proportion of HBsAg screening and prevalence of positive HBsAg were 69.2% and 9.0%, respectively. There was no difference in the proportion of no HBsAg screening during the period 1990-2008 (p = 0.865). Proportion of anti-HBs and anti-HBc screening were 40.9% and 21.2%, respectively. HBsAg was screened before or on the day of anti-HIV testing in 9.1% and before antiretroviral therapy (ART) initiation in 27.2%. By Kaplan-Meier analysis, median time from anti-HIV testing to HBsAg screening was 55.9 (95% confidence interval [CI] 43.9, 68.3) months. By multivariate logistic regression, duration of HIV infection (odds ratio [OR] 1.14; 95% CI 1.07, 1.21), no anti-HBs screening (OR 1.65; 95% CI 1.4-2.63), and no anti-HCV screening (OR 2.60; 95% CI 1.62, 4.17) were associated with no HBsAg screening before ART initiation. In conclusion, compliance with hepatitis B serology screening was relatively low and late. Educational program regarding hepatitis B serology screening, identification of barriers, and interventions to eliminate these barriers in resource-limited settings are crucial to improve HIV care.
Export Options
About this article
Cite this article as:
Kiertiburanakul Sasisopin, Chotiprasitsakul Darunee, Atamasirikul Kalayanee and Sungkanuparph Somnuek, Late and Low Compliance with Hepatitis B Serology Screening Among HIV-Infected Patients in a Resource-Limited Setting: An Issue to Improve HIV Care, Current HIV Research 2011; 9 (1) . https://dx.doi.org/10.2174/157016211794582669
DOI https://dx.doi.org/10.2174/157016211794582669 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mutation and Evolution of Antibiotic Resistance: Antibiotics as Promoters of Antibiotic Resistance?
Current Drug Targets Peptide Deformylase: A New Target in Antibacterial, Antimalarial and Anticancer Drug Discovery
Current Medicinal Chemistry Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Thyroid Nodules Classification using Weighted Average Ensemble and DCRITIC Based TOPSIS Methods for Ultrasound Images
Current Medical Imaging Alleviating the Neglected Tropical Diseases: Recent Developments in Diagnostics and Detection
Current Topics in Medicinal Chemistry Microwave-mediated Regiospecific Synthesis of Some Novel Annulated Spiro[indoline-3,1`-indolizin]-2-ones
Letters in Organic Chemistry A Novel Advanced Laboratory Diagnosis to Guide Tuberculosis Drug Therapy.
Recent Patents on Anti-Infective Drug Discovery Evaluation of Risk Factors for Development of Anti-Tubercular Therapy Induced Hepatotoxicity: A Prospective Study
Current Drug Safety Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews DHFS-ECM: Design of a Dual Heuristic Feature Selection-based Ensemble Classification Model for the Identification of Bamboo Species from Genomic Sequences
Current Genomics Electrospray Ionisation - Mass Spectrometry (ESI-MS) and Liquid Chromatography -Electrospray Ionisation - Mass Spectrometry (LC-ESI-MS) of Selected Pharmaceuticals
Current Pharmaceutical Analysis Beneficial Effects of Liposomal Formulations of Lichen Substances: A Review
Current Drug Delivery The Application of High Throughput siRNA Screening Technology to Study Host-Pathogen Interactions
Combinatorial Chemistry & High Throughput Screening Micronutrient Deficiency in Pulmonary Tuberculosis - Perspective on Hepatic Drug Metabolism and Pharmacokinetic Variability of First-line Anti- Tuberculosis Drugs: Special Reference to Fat-soluble Vitamins A, D, & E and Nutri-epigenetics
Drug Metabolism Letters The Potential of Mur Enzymes as Targets for Antimicrobial Drug Discovery
Current Drug Targets Antitubercular Properties of Substituted Hydroxycyclohexadienones
Letters in Drug Design & Discovery Pharmacologically Active Vanadium Species: Distribution in Biological Media and Interaction with Molecular Targets
Current Medicinal Chemistry A Comprehensive Review on Recent advances in Synthesis & Pharmacotherapeutic potential of Benzothiazoles
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Folate Pathway Inhibitors, An Underestimated and Underexplored Molecular Target for New Anti-tuberculosis Agents
Mini-Reviews in Medicinal Chemistry Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design